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Abstract
Background and Objectives: Natalizumab reduces the relapse rate and magnetic resonance imaging activity in patients
with Relapsing-Remitting Multiple Sclerosis (RRMS). So far the influence of natalizumab on cognitive functions and fatigue in
MS remains uncertain. The aim of this prospective, open-label, observational study was to evaluate the possible effects of
natalizumab on cognition and fatigue measures in RRMS patients treated for up to two years.
Methods: Cognitive performances were examined by the Rao’s Brief Repeatable Battery (BRB), the Stroop test (ST) and the
Cognitive Impairment Index (CII), every 12 months. Patients who failed in at least 3 tests of the BRB and the ST were
classified as cognitively impaired (CI). Fatigue Severity Scale (FSS) was administered every 12 months to assess patient’s self-
reported fatigue. One hundred and 53 patients completed 1 and 2 year-natalizumab treatment, respectively.
Results: After 1 year of treatment the percentage of CI patients decreased from 29% (29/100) at baseline to 19% (19/100)
(p=0.031) and the mean baseline values of CII (13.5266.85) and FSS (4.0161.63) scores were significantly reduced
(10.4867.12, p,0.0001 and 3.6161.56, p=0.008). These significant effects were confirmed in the subgroup of patients
treated up to two years.
Conclusions: These results demonstrate that a short-term NTZ treatment may significantly improve cognitive performances
and fatigue in RRMS patients.
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Introduction
Cognitive Impairment (CI) and fatigue are common features of
Multiple Sclerosis (MS), with an estimated prevalence ranging
approximately from 40 to 65% of patients [1–4]. Information
processing speed, abstract reasoning, executive functioning,
sustained attention and long-term memory are the most common
affected cognitive domains in MS [5]. CI detrimentally affects
many aspects of MS patient’ daily life, such as the ability to
participate fully in society and to maintain employment with a
consequent negative impact on the overall quality of life (QoL) [6].
In addition, the few data available on the natural history of CI and
fatigue in MS showed they tend to worsen during the disease
course [7–9] and correlate with disability progression [5,10]
measured by the Expanded Disability Status Scale (EDSS) [11].
Surprisingly, very little attention has been paid to cognition and
fatigue related outcomes in randomized clinical trials (RCTs) of
currently approved disease modifying drugs (DMDs), despite some
data suggested their potential neuroprotective effects [12–14].
Improvement in measures of information processing speed,
verbal memory and verbal learning has been reported in relapsing-
remitting (RR) MS patients treated with intramuscular Interferon
beta (IFNb)-1a [15] compared with placebo. IFNb-1b demon-
strated to improve visual memory in RRMS [16] and information
processing speed in patients with clinically isolated syndrome
suggestive of MS [17], and to delay the cognitive decline in
patients with secondary progressive MS [18]. Recently, a
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35843longitudinal observational study demonstrated a beneficial dose-
related effect of subcutaneous IFNb-1a on cognitive functions in
RRMS patients [19]. Until now, the impact of the IFNb on fatigue
is still controversial [20–22].
Glatiramer Acetate (GA) treatment failed to demonstrate
significant effects on cognition, even in a long-term follow-up
[23,24], whereas some significant effects of GA on fatigue have
been shown [25].
A post hoc analysis of the two pivotal trials of natalizumab
(NTZ), AFFIRM [26] and SENTINEL [27], suggested a positive
effect of NTZ on both the physical and mental domains of Health
Related QoL [28]. More recently, data from observational studies,
involving small groups of patients [29,30], or using only one
cognitive test [31], suggested that NTZ treatment may impact
cognitive performances and fatigue [32] in patients with RRMS.
Here we report the results of an open label, prospective,
observational study aimed to further assess the effect of NTZ on
cognition and fatigue in a large population of RRMS patients who
were followed for up to two years.
Methods
Patients
All the MS patients who started the standard NTZ regimen
(300 mg ev monthly) treatment in two Italian academic (Bari and
Florence) MS centers from 2007 were followed through scheduled
clinical and neuropsychological assessments. The relapses oc-
curred in the last year prior to the treatment and every new relapse
occurring during the treatment were recorded. Annualized relapse
rate (ARR) in the last year pre-treatment (baseline) and at the end
of the first and second year of treatment was calculated for each
patient. A complete neurological examination including the EDSS
score assessment was performed at baseline and every 3 months
throughout treatment. Cognitive functioning, using the Rao’s Brief
Repeatable Battery (BRB) [5,33] and the Stroop Test (ST), was
measured before the first infusion and every 12 months by a
trained psychologist in each center. BRB included tests of verbal
memory acquisition and delayed recall (Selective Reminding Test
– SRT), visual memory acquisition and delayed recall (10/36
Spatial Recall Test – SPART), attention, concentration and speed
of information processing (PASAT 3; PASAT 2; Symbol Digit
Modalities Test – SDMT), and verbal fluency on semantic
stimulus (Word List Generation – WLG). Frontal lobe executive
functions were assessed by the Stroop color-word task (ST).
Versions A and B of the BRB were used alternatively at each
examination.
Cognitive impairment was defined as the failure in at least 3
tests on BRB and ST using a 5
th percentile cut-off for each test,
which corresponded to a z-score 2 standard deviation (SD) below
the mean Italian normative values [33]. A global score, defined
Cognitive Impairment Index (CII), allowing the evaluation of
changes in cognitive performances independently by the number
of cognitive tests failed at the BRB and the ST, was obtained using
the mean and SD from the normative sample of Rao’s battery and
the ST [19,34]. For each patient, a grading system was applied to
individual cognitive tests, based on the number of SDs below the
control mean (i.e. grade 0 was given if the patient scored at or
above the control mean, 1 if he/she scored below the control
mean, but at or above 1 SD below the control mean, and so on
until all patient scores were accommodated). Finally, all the
patient’s scores were summed to give one overall measure of
cognitive function.
Fatigue and depression were respectively, assessed, by the
Fatigue Severity Scale (FSS) [35], using a cut-off value of 4.5 to
identify patients with a level of fatigue interfering with daily
activities, and by the Beck Depression Inventory (BDI) [36], using
a cut-off value of 9 to identify patients with at least mild depressive
symptoms, at baseline and every 12 months. If a relapse occurred
at the time of scheduled neuropsychological assessments, cognitive
testing was delayed until 30 days after the last steroid
administration. Patients with a visual function impairment
interfering with the performances in the cognitive tests were not
included in the study. All the patients who reached 1 and 2 years
of NTZ treatment entered into the analyses.
The local Ethics Committees of the University of Bari and of the
University of Florence approved the study, and written informed
consent was obtained from all patients prior to entering the study.
Statistical analyses
Descriptive analyses were performed at the baseline. No
imputation of missing data was considered. To test differences
across different time points in related samples non parametric tests
were used. The Wilcoxon signed – rank test for paired samples and
the Friedman two-way test for repeated measures with post-hoc
correction were used to compare mean values in paired
examinations or when three or more evaluations were available
for continuous variables. Cochran Q test for repeated measures
and McNemar test for pairwise comparisons were used to assess
changes over time in categorical variables. A value of p,0.05 was
considered significant for the Wilcoxon signed – rank test, the
Friedman two-way test and the Cochran Q test. For post-hoc
multiple comparisons, we elected a pre-assigned p/number of
comparisons (Bonferroni’s correction) as the threshold for
significance, and therefore, a p,0.017 (0.05/3) was used as a
definition of statistical significance for n=3 comparisons.
Multivariate logistic regressions were performed to evaluate
potential clinical and demographic confounders which can affect
the changes of neuropsychological performances and fatigue scores
at the end of the 1st year of NTZ treatment. In these models the
following variables: sex, age, time spent in formal school
education, disease duration, BDI score, time from the last steroid
pulse to start of NTZ treatment, ARR in last year prior NTZ
treatment, baseline EDSS, baseline FSS score and baseline CII,
were included as covariates; ‘‘improved and stable’’ and
‘‘worsened’’ FSS score or CII were considered as dependent
variables. Data analyses were performed by SPSS 17.0.
Results
At the end of September 2011, 100 and 53 RRMS patients
completed 1 and 2 years of treatment, respectively. Patients’
demographic and clinical characteristics at baseline are shown in
Table 1. In patients completing 1 year-NTZ treatment, the mean
ARR at baseline (1.9160.82) and the mean baseline EDSS score
(3.6661.14) significantly decreased at the end of follow-up
(0.2860.53, p,0.0001; 3.5161.24, p=0.005).
In the subgroup of patients receiving NTZ for two years, the
mean ARR and the mean EDSS score significantly decreased
during the treatment (Friedman test: p,0.0001 and p=0.011,
respectively). A Wilcoxon signed-rank test with a Bonferroni
correction for multiple tests showed that the ARR significantly
improved after 1 (0.2360.42; p,0.0001) and 2 years (0.1860.43;
p,0.0001) in comparison to baseline value (1.9860.87). There
were no significant differences between year 1 and 2 of treatment
(p=N.S.). A significant reduction of the baseline EDSS score
(3.5861.12) was also observed at 1 year (3.3561.17, p=0.001),
whereas no significant difference was found at year 2 (3.4861.43;
p=N.S.). At the baseline the median BDI score was 9, ranging
Cognition and Fatigue during Natalizumab Treatment
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and were classified as patients with depressive symptoms.
(Table 1). The mean BDI score (10.3666.94) significantly
decreased after 1 (9.4867.47; p=0.001) and 2 years (n=53;
9.0766.74; p=0.001) of NTZ treatment.
Cognitive impairment
At baseline 29/100 (29%) of RRMS patients failed in at least
three tests of the BRB and the ST and were classified as cognitively
impaired. In patients completing 1 year-NTZ treatment, the
number of patients cognitively impaired decreased to 19/100
(19%) (p=0.031) (Table 2). Accordingly, the mean CII values
were found to be significantly reduced at year 1 in comparison to
baseline values (p,0.0001) (Table 3).
In the subgroup of patients receiving NTZ for two years, the
percentage of cognitively impaired patients decreased from 22.6%
(12/53) to 18.9% (10/53) at 1 year and to 17% (9/53) at 2 years,
although this decrease did not achieve the statistical significance
(Cochran Q test, p=N.S.)(Table 2).
In patients treated for up to 2 years the CII significantly
decreased (Friedman test: p,0.0001). A Wilcoxon signed-rank test
with a Bonferroni correction for multiple tests showed that the CII
significantly improved after 1 (9.6466.89; p,0.0001) and 2 years
(8.2666.75; p,0.0001) in comparison to baseline value
(12.9467.09). The CII also furtherly decreased in the second year
oftreatmentincomparisontotheyear1value(p=0.008)(Table3).
The results of the multivariate logistic regression (Table 4)
showed that educational school level positively impacted
[OR:1.217; 95% Confidence Interval=1.008–1.468; p=0.041]
the improvement of neuropsychological performances at the end
of the 1
st year of treatment, whereas sex, age, disease duration,
BDI score, time from the last steroid pulse to start of NTZ
treatment, ARR in last year prior NTZ treatment, baseline EDSS,
baseline FSS score did not have any influence.
Table 5 shows in detail the mean scores of each cognitive test
at the different time points. A significant difference between the
baseline values and those at 1 year was found only for SPART
(p=0.037), SDMT (p,0.0001) and PASAT 2 (p=0.026) scores. In
the subgroup of patients with two year treatment a significant
Table 1. Demographic and clinical characteristics at baseline.
Variable 100 patients 53 patients
with 1 year with 2 years
NTZ NTZ
Treatment Treatment
Sex (F/M) 72/28 37/16
Age at baseline (Mean 6SD)* 34.5569.25 33.4168.85
Disease duration in years (Mean 6SD)* 11.0967.52 9.6766.14
Educational level years (Mean 6SD)* 12.5163.27 12.5663.63
ARR (Mean 6SD) 1.9160.82 1.9860.87
EDSS (Mean 6SD) 3.6661.14 3.5861.12
Number of previous DMDs treatment (Median (Range)) 2 (0–4) 2 (0–4)
Last DMD (n and %) Interferon-beta 79 (79%) 42 (79.2%)
Glatiramer Acetate 14 (14%) 7 (13.2%)
Mitoxantrone 1 (1%) 0
Azathioprine 2 (2%) 1 (1.9%)
Treatment naı ¨ve 4 (4%) 3 (5.7%)
Previous treatment duration (Mean 6SD){ 53.99641.53 55.99641.67
BDI score (median; Range) 9 (0–32) 9 (0–28)
Absence/Presence of No Depression (0–9) 56 28
Depression by the Mild Depression (10–18) 26 13
BDI score Moderate Depression (19–29) 17 12
Severe Depression (30–63) 1 0
*Data expressed in years; {Data expressed in months
Abbreviations: NTZ=Natalizumab; ARR=Annualized Relapse Rate; EDSS=Expanded Disability Status Scale; DMD=Disease Modifying Drug; BDI=Beck Depression
Inventory.
doi:10.1371/journal.pone.0035843.t001
Table 2. Changes of proportion of RRMS patients with






without CI Proportion of
patients with CI
Baseline (n=100) 29 71 29%
Year 1 19 81 19%
Baseline (n=53) 12 41 22.6%
Year 1 10 43 18.9%
Year 2 9 44 17%
doi:10.1371/journal.pone.0035843.t002
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PASAT 2 (p,0.0001) performances was still evident at the end of
the follow-up in comparison to baseline values. The Wilcoxon
signed-rank test with a Bonferroni correction for multiple tests
showed that the SDMT, and the PASAT 2 performances
significantly improved after 1 (p=0.001 and p=0.003, respective-
ly) and 2 years (p,0.0001) in comparison to baseline values. There
were no significant differences between year 1 and 2 of treatment
(p=0.088 and p=0.080, respectively). Furthermore, in these
patients an improvement in the PASAT 3 (p=0.005) performanc-
es was found in the 2
nd year of treatment.
Fatigue
At baseline the mean FSS score was 4.01 (61.63), and 45/100
patients (45%) reported levels of fatigue which interfered with daily
activities (FSS score $4.5). After 1 year of NTZ treatment, the
mean FSS score significantly decreased to 3.61 (61.56) (p=0.008)
(Table 3) and the proportion of patients with FSS score $4.5
decreased to 29% (29/71, p=0.005). In patients with a 2 year-
follow-up, the mean FSS score significantly decreased during the
treatment (Friedman test, p=0.001). A Wilcoxon signed-rank test
with a Bonferroni correction for multiple tests showed that the
mean FSS score significantly improved after 1 (p=0.004) and 2
years (p=0.001) in comparison to baseline values. There were no
significant differences between year 1 and 2 of treatment (p=N.S.)
(Table 3). In this subgroup the proportion of patients with FSS
score $4.5 significantly (Cochran Q test, p=0.01) decreased
during the 2 years NTZ treatment from 52.8% (28/53 patients) to
32.1% (17/53 patients) at year 1 and to 34% (18/53 patients) at
year 2. A McNemar test with a Bonferroni correction for multiple
Table 3. Changes of mean Cognitive Impairment Index (CII)
values and of the mean FSS Score over 1 and 2 years of NTZ
treatment.
Parameter Timepoint Mean [SD] p value
CII (n=100) Baseline 13.52 [6.85] ,.0001
*
Year 1 10.48 [7.12]
CII (n=53) Baseline 12.94 [7.09] ,.0001
{
Year 1 9.64 [6.89] ,.0001
1
Year 2 8.26 [6.75] .008
h
FSS (n=100) Baseline 4.01 [1.63] .008*
Year 1 3.61 [1.56]
FSS (n=53) Baseline 4.30 [1.58] .004 {
Year 1 3.70 [1.41] N.S.h
Year 2 3.49[1.75] .0011
*Wilcoxon signed-rank test;
{Wilcoxon signed-rank test pair-wise comparison: Year 1 vs Baseline;
1Wilcoxon signed-rank test pair-wise comparison: Year 2 vs Baseline;
hWilcoxon signed-rank test pair-wise comparison: Year 1 vs Year 2.
doi:10.1371/journal.pone.0035843.t003
Table 4. Baseline predictors of improvement of the Cognitive Impairment Index (CII) and of the Fatigue Severity Scale (FSS) at 1
year of NTZ treatment: multivariate logistic regression analysis.
Parameter Baseline OR 95%Confidence p value
Variable Interval
Improvement of CII Constant 2.492 0.719
at year 1 (n=100) Sex 1.367 (0.399–4.688) 0.619
Age 0.957 (0.894–1.025) 0.210
Disease Duration 0.991 (0.913–1.077) 0.834
Educational School level 1.217 (1.008–1.468) 0.041
EDSS 0.984 (0.559–1.733) 0.956
FSS score 0.844 (0.571–1.248) 0.396
BDI score 1.021 (0.940–1.110) 0.621
Time from the last steroid
Pulse 0.974 (0.760–1.250) 0.840
ARR 0.736 (0.385–1.405) 0.352
Improvement of FSS Constant 4.140 0.518
at year 1 (n=100) Sex 1.029 (0.317–2.865) 0.956
Age 0.973 (0.917–1.032) 0.359
Disease Duration 1.012 (0.940–1.090) 0.748
Educational School level 0.966 (0.821–1.135) 0.672
EDSS 0.848 (0.524–1.374) 0.504
BDI score 1.028 (0.956–1.105) 0.460
CII 0.974 (0.904–1.049) 0.487
Time from the last steroid
Pulse 1.000 (0.820–1.220) 0.998
ARR 0.948 (0.502–1.790) 0.869
Abbreviations: ARR=Annualized Relapse Rate; EDSS=Expanded Disability Status Scale; BDI=Beck Depression Inventory.
doi:10.1371/journal.pone.0035843.t004
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patients with FSS score $4.5 after 1 (p=0.019) and 2 years
(p=0.021) in comparison to baseline value. There were no
significant differences between year 1 and 2 of treatment (p=N.S.).
The results of the multivariate logistic regression (Table 4) did
not show any significant effect of the baseline covariates (sex, age,
time spent in formal school education, disease duration, BDI
score, time from the last steroid pulse to start of NTZ treatment,
ARR in last year prior NTZ treatment, baseline EDSS, and




The results of this observational study confirm the efficacy of
NTZ treatment in reducing disease activity and disability
progression in RRMS patients already demonstrated in NTZ
pivotal trials [26,27]. In addition they show that a short-term NTZ
treatment may significantly improve cognitive performances and
fatigue in these patients. A decrease of the proportion of
cognitively impaired MS patients and an improvement of
sustained attention, information processing speed and visuo-spatial
memory, as measured by the SDMT, PASAT 2 and SPART, were
evident since the first year of NTZ treatment. Most of these
beneficial effects on cognition were still present after two years of
treatment. These findings are consistent with previously published
Italian [29,30] and Swedish [31] observational studies suggesting a
beneficial effect of NTZ on cognitive performances. In the Italian
study, even if a smaller number of patients (n=39 at 1 year; n=11
at 2 years) than in the current study was evaluated and the
cognitive impairment was assessed by a neuropsychological battery
different from the BRB we used, an improvement in tests which
explore information processing speed, executive function and
memory tests were also found [29,30]. Data from the Swedish
post-marketing surveillance program of MS patients treated with
NTZ for up to 2 years, clearly demonstrate an improvement in
SDMT [31].
It is noteworthy that in the current study we used, also, a
measure of the global change of cognitive performances that is the
CII. We found a significant improvement in the mean CII value
after 1 year NTZ treatment and this value was furtherly improved
in the second year of treatment. The CII [19,34] may be
considered a more suitable tool to evaluate changes in cognitive
performances than considering the individual tests, because CII is
independent by the number of cognitive tests failed at the BRB
and the ST (i.e. if an individual patient was impaired in six tests at
baseline and failed four tests at follow-up, that patient would be
still considered cognitively impaired, despite the fact that his or her
performances were objectively improved), therefore its use
strengthens the results of this study. Moreover in this study we
used alternate versions of cognitive tests, and adequate time
intervals between them to reduce the major methodological issue
when neuropsychological tests are repeated over time that is the
practice effect [37,38].
The significant improvement of fatigue measures after 1 and 2
years of NTZ treatment that we have found, is also in line with a
previous German study [32] that showed a decrease of fatigue in
RRMS treated with NTZ for 6 months.
Table 5. Changes of mean scores for each cognitive test after 1 and 2 years of NTZ treatment.
1 year Treatment (n=100) 2 years Treatment (n=53)
Baseline Year 1 Baseline Year 1 Year 2
Verbal
Memory
SRT-LTS 35.20 (13.90) 36.68 (13.58) 35.49 (14.10) 37.94 (13.94) 36.64 (15.09)
SRT-CTLR 26.83 (14.60) 26.67 (14.87) 28.15 (14.63) 28.32 (15.58) 28.24 (16.65)
SRT-D 7.11 (2.65) 7.54 (3.62) 7.13 (2.55) 7.98 (4.41) 7.34 (3.93)
Spatial
Memory
SPART 17.65 (6.14) 18.90 (6.04)* 18.58 (6.36) 18.40 (6.47) 19.68 (5.99)
SPART-D 6.30 (3.48) 6.51 (2.55) 6.85 (4.10) 6.66 (2.56) 6.60 (2.17)
Attention
SDMT 42.87 (12.33) 46.29 (12.44)** 43.32 (12.99) 48.06 (12.09) 49.57 (12.92)
{
PASAT-3 34.01 (14.02) 34.24 (14.94) 35.75 (14.53) 36.34 (14.80) 38.88 (14.46)
{




WLG 19.98 (6.02) 20.48 (5.79) 20.81 (5.66) 20.41 (5.42) 22.15 (5.48)
ST 70.90 (15.18) 69.98 (18.45) 69.35 (13.70) 69.40 (13.27) 65.42 (14.30)
*p,0.05 (Wilcoxon signed-rank test);
**p,0.0001 (Wilcoxon signed-rank test);
{p,0.01 (Friedman two-way test);
Abbreviations: SRT-LTS=Selective Reminding Test – Long-Term Storage; SRT-CTLR=Selective Reminding Test – Consistent Long-Term Retrieval; SRT-D=Selective
Reminding Test –Delayed; SPART=10/36 Spatial Recall Test; SPART-D=10/36 Spatial Recall Test-Delayed; SDMT=Symbol Digit Modalities Test; PASAT 3=Paced
Auditory Serial Addition Test three second rate; PASAT 2=Paced Auditory Serial Addition Test two second rate; WLG=Word List Generation; ST=Stroop Test.
Values are expressed as Mean (SD).
doi:10.1371/journal.pone.0035843.t005
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which could affect the changes of neuropsychological performanc-
es and fatigue scores at the end of the 1st year of treatment was
ruled out by a logistic regression analysis that demonstrated that
both cognitive impairment and fatigue were independent from
other clinical variables, in this cohort. The only covariate with a
positive predictive effect on the neuropsychological performances
was the educational level, as measured by the time spent in formal
school education, in accordance with recent reports [39–41]
showing a significant beneficial effect of the so-called brain reserve
on cognition and on the brain atrophy progression in MS.
The degree and the time-trend of the improvement induced by
NTZ on cognitive functions and fatigue in the current and
previous studies [29–32] seem to suggest that these two
phenomena could be, at least in mild disabled patients, more
related to inflammation than to neurodegeneration mechanisms. A
growing evidence seems to support this view. In the experimental
autoimmune encephalomyelitis (EAE), the rodent model of MS, it
was recently demonstrated that the activation of microglia and the
inflammatory cytokines released from infiltrating lymphocytes,
especially TNF-a, are able to alter synaptic transmission [42,43].
This induced synaptopathy is related to cognitive dysfunction in
this experimental model of MS [42,43]. The significant reduction
of cerebrospinal fluid (CSF) and plasma levels of pro-inflammatory
cytokines and of CSF levels of the light-chain neurofilament, a
marker of axonal loss, during the NTZ treatment [14,44,45] may
be responsible of the cognitive dysfunction improvement induced
by NTZ. Moreover 1 year NTZ treatment has been demonstrated
to prevent the accumulation of active cortical lesions in RRMS, an
MRI measure that is correlated with cognitive decline [46].
We recognize that the main limit of this observational study is
the lack of a concurrent control group. However it must be
considered that many barriers may prevent the execution of a
controlled observational study aimed to evaluate the effects of a
second line drug (i.e. NTZ) on a population of MS patients with
high disease activity. The inclusion of a placebo group, that
remains untreated for up to 2 years, is not feasible and ethical.
Moreover a comparison between patients treated with a second
line treatment (NTZ) and patients treated with a first line
treatment (IFN b or GA) is also difficult to carry out, because
the unbalanced baseline measures of disease activity (i.e. ARR,
EDSS, MRI) between the two groups (indication bias) may
influence the measured association between exposure and
outcome. Within-subject methods, including self-controlled case-
series method [47] as we used in this study, in which outcomes are
compared between periods before and after treatment exposure
within the same individuals, are less susceptible to confounding by
indication and may eliminate between-person confounding [48].
Nevertheless an analysis is ongoing aimed to identify a suitable
active drug control group among the DMD treated MS patients
collected, in the same period of time, in the MS databases (Imed-
web) in Bari and Florence Centers. We are using a propensity
score matching technique [49,50], which is the most common
method currently used to reduce bias in treatment comparisons in
observational studies [51,52] to select patients whose demograph-
ics and disease characteristics overlap with those of our cohort of
NTZ-treated patients, and that were evaluated for cognitive
impairment at the same time-point of the NTZ-treated cohort. A
preliminary analysis [data not shown] on a sample of 20 RRMS
patients (mean 6 SD: age: 35.12610.99; disease duration:
10.3269.92; mean EDSS 3.561.14; mean ARR in the year
before the treatment initiation: 1.9560.85) treated with different
formulations of DMDs was performed. The results showed that
DMD treatment reduced the baseline mean CII values over a two
year follow-up (mean [SD] Baseline CII: 14.61 [6.62]; mean [SD]
1 Year CII: 13.06 [6.03]; mean [SD] 2 Years CII: 12.78 [6.06] in
these sample of patients, but this effect did not reach a statistical
significance, Friedmann two-way test: p=0.241). However the
lack of statistical significance could be due to the small sample size
of this DMD treated group. So far, few studies reported some
beneficial effects of IFN beta treatment on cognitive functions in
RRMS patients [15–19], whereas GA treatment failed to
demonstrate any significant effect on cognition [23,24], but only
some significant effects on fatigue measures [25].
Although no direct comparison could be made, our findings
allow to speculate that the effects of NTZ on both cognition and
fatigue measures might be greater than first line DMDs.
A longer follow-up in a larger population, including a
propensity score matched control group, is needed to confirm
whether the early beneficial effects of NTZ in improving cognitive
performances and fatigue, we found in this study, hold-up in the
long-term.
Author Contributions
Conceived and designed the experiments: MT PI RGV. Performed the
experiments: PI RGV DP GL EP BG VD MD MPA MT SZ. Analyzed the
data: PI MT. Wrote the paper: PI RGV MT.
References
1. Chiaravallotti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis.
Lancet Neurol Dec; 7: 1139–51.
2. Rao SM, Leo GJ, St Aubin-Faubert P (1989) On the nature of memory
disturbance in multiple sclerosis. J Clin Exp Neuropsychol 11: 699–712.
3. Rao SM, St Aubin-Faubert P, Leo GJ (1989) Information processing speed in
patients with multiple sclerosis. J Clin Exp Neuropsychol 11: 471–7.
4. Bakshi R (2003) Fatigue associated with multiple sclerosis: diagnosis, impact and
management. Mult Scler 9: 219–27.
5. Rao SM, Leo GJ, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in
multiple sclerosis. I. Frequency, patterns and prediction. Neurology 41:
685–691.
6. Amato MP, Zipoli V (2003) Clinical management of cognitive impairment in
multiple sclerosis: a review of current evidence. Int MS J 10: 72–83.
7. Amato MP, Ponziani G, Siracusa G, Sorbi S (2001) Cognitive dysfunction in
early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 58:
1602–6.
8. Amato MP, Zipoli V, Portaccio E (2006) Multiple sclerosis-related cognitive
changes: a review of cross-sectional and longitudinal studies. J Neurol Sci 245:
41–46.
9. Patrick E, Christodoulou C, Krupp LB, New York State MS Consortium (2009)
Longitudinal correlates of fatigue in multiple sclerosis. Mult Scler 15: 258–61.
10. Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F, et al. (2005)
Predicting quality of life in multiple sclerosis: accounting for physical disability,
fatigue, cognition, mood disorder, personality and behavior change. J Neurol Sci
231: 29–34.
11. Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an
Expanded Disability Status Scale (EDSS). Neurology 33: 1444–1452.
12. Rudick RA (1999) Disease-modifying drugs for relapsing-remitting multiple
sclerosis and future directions for multiple sclerosis therapeutics. Arch Neurol 56:
1079–84.
13. Arnon R, Aharoni R (2009) Neuroprotection and neurogeneration in MS and its
animal model EAE effected by glatiramer acetate. J Neural Transm 116:
1443–9.
14. Gunnarsson M, Malmestro ¨m C, Axelsson M, Sundstro ¨m P, Dahle C, et al.
(2010) Axonal damage in relapsing multiple sclerosis is markedly reduced by
natalizumab. Ann Neurol 69: 83–9.
15. Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, et al. (2000)
Neuropsychological effects of interferon b-1a in relapsing multiple sclerosis. Ann
Neurol 48: 885–892.
16. Pliskin NH, Hamer DP, Goldstein DS, Towle VL, Reder AT, et al. (1996)
Improved delayed visual reproduction test performance in multiple sclerosis
patients receiving interferon b-1b. Neurology 47: 1463–1468.
17. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, et al. (2009)
Long-term effect of early treatment with interferon beta-1b after a first clinical
event suggestive of multiple sclerosis: 5-year active treatment extension of the
phase 3 BENEFIT trial. Lancet Neurol 8: 987–97.
Cognition and Fatigue during Natalizumab Treatment
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e3584318. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, et al. (2002)
Benefit of interferon b-1a on MSFC progression in secondary progressive MS.
Neurology 59: 679–687.
19. Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, et al. (2010) Effects of
immunomodulatory treatment with subcutaneous interferon beta-1a on
cognitive decline in mildly disable patients with relapsing remitting multiple
sclerosis. Mult Scler 16: 68–77.
20. Metz LM, Patten SB, Archibald CJ, Bakker JI, Harris CJ, et al. (2004) The effect
of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol
Neurosurg Psychiatry 75: 1045–7.
21. Yildiz M, Tettenborn B, Putzki N (2011) Multiple sclerosis-associated fatigue
during disease-modifying treatment with natalizumab, interferon-beta and
glatiramer acetate. Eur Neurol 65: 231–2.
22. Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, et al. (2011) Quality of
life, depression and fatigue in mildly disabled patients with relapsing-remitting
multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from
the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study. Mult
Scler 17: 991–1001.
23. Weinstein A, Schwid SR, Schiffer RB, McDermott MP, Giang DW, et al. (1999)
Neuropsychological status in multiple sclerosis after treatment with glatiramer.
Arch Neurol 56: 319–324.
24. Schwid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP (2007)
Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year
clinical trial. J Neurol Sci 255: 57–63.
25. Ziemness THJ, Apfel R, Kern S (2008) Effects of glatiramer acetate on fatigue
and days of absence from work in first-time treated relapsing-remitting multiple
sclerosis. Health Qual Life outcomes 6: 1–6.
26. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, et al.
(2006) A randomized, placebo-controlled trial of natalizumab for relapsing
multiple sclerosis. N Engl J Med 354: 899–910.
27. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, et al. (2006)
Natalizumabplusinterferonbeta-1aforrelapsingmultiplesclerosis.NEnglJMed
354: 911–923.
28. Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, et al. (2007) Health-
Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab. Ann
Neurol 62: 335–346.
29. Mattioli F, Stampatori C, Bellomi F, Capra R (2011) Natalizumab efficacy on
cognitive impairment in MS. Neurol Sci 31 Suppl 3: 321–3.
30. Mattioli F, Stampatori C, Capra R (2011) The effect of natalizumab on
cognitive function in patients with relapsing-remitting multiple sclerosis:
preliminary results of a 1-year follow-up study. Neurol Sci 32: 83–8.
31. Piehl F, Holme ´n C, Hillert J, Olsonn T (2011) Swedish natalizumab (Tysabri)
multiple sclerosis surveillance study. Neurol Sci 31 Suppl 3: 289–93.
32. Putzki N, Yaldizli O, Tettenborn, Diener HC (2009) Multiple sclerosis
associated fatigue among natalizumab treatment. J Neurol Sci 285: 109–13.
33. Amato MP, Portaccio E, Goretti B, Zipoli V, Ricchiuti L, et al. (2006) The Rao’s
Brief Repeatable Battery and Stroop Test: normative values with age, education
and gender corrections in an Italian population. Mult Scler 12: 787–793.
34. Camp SJ, Stevenson VL, Thompson AJ, Miller DH, Borras C, et al. (1999)
Cognitive function in primary progressive and transitional progressive multiple
sclerosis. A controlled study with MRI correlates. Brain 122: 1341–1348.
35. Krupp LB, LaRocca NG, Muir-Nash J, Steinbrg AD (1989) The fatigue severity
scale. Application to patients with multiple sclerosis and systemic lupus
erythematosus. Arch Neurol 46: 1121–3.
36. Beck AT, Ward CH, Medelson M, et al. (1961) An inventory for measuring
depression. Arch Gen Psychiatry 4: 561–71.
37. Portaccio E, Goretti B, Zipoli V, Iudice A, Pina DD, Malentacchi GM, et al.
(2010) Reliability, practice effects, and change indices for Rao’s brief repeatable
battery. Mult Scler May;16(5): 611–7.
38. Johnson BF, Hoch K, Johnson J (1991) Variability in psychometric test scores:
the importance of the practice effect in patient study design. Prog
Neuropsychopharmacol Biol Psychiatry 15: 625–635.
39. Sumowski JF, Chiaravalloti N, Wylie G, Deluca J (2009) Cognitive reserve
moderates the negative effect of brain atrophy on cognitive efficiency in multiple
sclerosis. J Int Neuropsychol Soc 15: 606–12.
40. Sumowski JF, Wylie GR, Deluca J, Chiaravalloti N (2010) Intellectual
enrichment is linked to cerebral efficiency in multiple sclerosis: functional
magnetic resonance imaging evidence for cognitive reserve. Brain 133(Pt 2):
362–74.
41. Sumowski JF, Wylie GR, Chiaravalloti N, DeLuca J (2010) Intellectual
enrichment lessens the effect of brain atrophy on learning and memory in
multiple sclerosis. Neurology 74: 1942–5.
42. Mandolesi G, Grasselli G, Musumesi G, Centonze D (2010) Cognitive deficits in
experimental autoimmune encephalomyelitis: neuroinflammation and synaptic
degeration. Neurol Sci 31(Suppl 2): S255–S259.
43. Centonze D, Muzio L, Rossi S, Cavasinni F, De Chiara V, et al. (2009)
Inflammation triggers synaptic alteration and degeneration in experimental
autoimmune encephalomyelitis. J Neurosci 29: 3442–3452.
4 4 .M e l l e r g a r dJ ,E d s t r o mM ,V r e t h e mM ,E r n e u r d hJ ,D a h l eC( 2 0 1 0 )
Natalizumab treatment in multiple sclerosis: marked decline of chemokines
and cytokines in cerebrospinal fluid. Mult Scler 16: 208–217.
45. Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, et al. (2009) The
effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects
for treatment-sensitive biomarkers. Eur J Neurol 16: 528–536.
46. Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P (2011)
Natalizumab prevents the accumulation of cortical lesions in relapsing remitting
multiple sclerosis: a preliminary report. Neurol Sci Suppl 3: 317–20.
47. Whitaker HJ, Farrington CP, Spiessens B, Musonda P (2006) Tutorial in
biostatistics: the self-controlled case series method. Stat Med 25: 1768–9750.
48. Schneeweiss S, Sturmer T, Maclure M (1997) Case-crossover and case time-
control designs as alternatives in pharmacoepidemiologic research. Pharmacoe-
pidemiol Drug Saf 6(Suppl. 3): S51–915.
49. Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in
observational studies for causal effects. Biometrika 70: 41–55.
50. Rosenbaum PR, Rubin DB (1984) Reducing bias in observational studies using
subclassification on the propensity score. J Am Statist Assoc 79: 516–24.
51. Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, et al. (2007) New
natural history of Interferon-b-treated relapsing Multiple Sclerosis. Ann Neurol
61: 300–306.
52. Trojano M, Pellegrini F, Paolicelli D, et al. (2009) Real-Life Impact of Early
Interferon- b therapy in Relapsing Multiple Sclerosis. Ann Neurol 66: 513–520.
Cognition and Fatigue during Natalizumab Treatment
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35843